ADAP - アダプティミュ―ン・セラピュ―ティクス (Adaptimmune Therapeutics plc)

ADAPのニュース

   The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance  2020/01/15 13:22:46 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 14.) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ): announced an oncology stem cell therapy pact with Astellas Pharma Inc. (OTC: ALPMY ). Applied Therapeutics Inc (NASDAQ: APLT ) Arvinas Inc (NASDAQ: ARVN ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Calithera Biosciences Inc (NASDAQ: CALA ) Editas Medicine Inc (NASDAQ: EDIT ) Eli Lilly And Co (NYSE: LLY ) Epizyme Inc (NASDAQ: EPZM ) Fate Therapeutics Inc (NASDAQ: FATE ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (provided 2020 guidance) Hologic, Inc. (NASDAQ: HOLX ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novo Nordisk A/S (NYSE: NVO ) NuVasive, Inc. (NASDAQ: NUVA ) Profound Medical Corp (NASDAQ: PROF ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) Revance Therapeutics Inc (NASDAQ: RVNC ) Syneos Health, Inc. (NASDAQ: SYNH ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Varian Medical Systems, Inc. (NYSE: VAR ) Viela Bio Inc (NASDAQ: VIE ) West Pharmaceutical Services Inc. (NYSE: WST ) XBiotech Inc (NASDAQ: XBIT ) (announced a tender offer to buy up to $420 million worth …
   Adaptimmune Soars 250% On Positive Initial Responses For T-Cell Platform In 4 Tumor Types  2020/01/13 17:50:33 Benzinga Feeds
Shares of smid-cap biotech Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) were skyrocketing Monday following a presentation at the 38t
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   Cowen Reaffirms “Buy” Rating for Adaptimmune Therapeutics (NASDAQ:ADAP)  2019/11/11 23:15:34 Modern Readers
Cowen reaffirmed their buy rating on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued to investors on Thursday, AnalystRatings.com reports. ADAP has been the subject of several other reports. Guggenheim lowered shares of Adaptimmune Therapeutics from a buy rating to a neutral rating in a research report on Thursday, August 1st. BidaskClub lowered […]
   Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds  2019/10/31 17:52:52 ACI Information Group
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   Cowen Reaffirms “Buy” Rating for Adaptimmune Therapeutics (NASDAQ:ADAP)  2019/11/11 23:15:34 Modern Readers
Cowen reaffirmed their buy rating on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued to investors on Thursday, AnalystRatings.com reports. ADAP has been the subject of several other reports. Guggenheim lowered shares of Adaptimmune Therapeutics from a buy rating to a neutral rating in a research report on Thursday, August 1st. BidaskClub lowered […]
   Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds  2019/10/31 17:52:52 ACI Information Group
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry
   The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug  2019/10/25 11:12:03 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise quarter) Edwards Lifesciences Corp (NYSE: EW )( reported better-than-expected third-quarter results) Frequency Therapeutics Inc (NASDAQ: FREQ ) (IPOed Oct. 3) GlaxoSmithKline plc (NYSE: GSK )(FDA approved expanded use of Zejula) Novo Nordisk A/S (NYSE: NVO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 24) Acorda Therapeutics Inc NASDAQ: ACOR) (announced restructuring plan, including the elimination of 25% of its workforce) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) bluebird bio Inc (NASDAQ: BLUE ) (announced resignation of chief strategy officer) Brickell Biotech Inc (NASDAQ: BBI ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Gritstone Oncology Inc (NASDAQ: GRTS ) KemPharm Inc (NASDAQ: KMPH ) MacroGenics Inc (NASDAQ: MGNX ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) OpGen Inc (NASDAQ: OPGN ) )(announcing pricing of previously-announced underwritten common stock offering) Opko Health Inc. (NASDAQ: OPK )(announced a follow-on offering) Orgenesis Inc (NASDAQ: ORGS ) Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN ) Titan Medical Inc. (NASDAQ: TMDI ) Stocks In Focus Melinta Gets FDA Nod For Baxdela Label Expansion; Launch to Be Delayed Due to Liquidity Concerns Melinta Therapeutics Inc (NASDAQ: MLNT ) announced FDA approval for Baxdela for the treatment of adult patients with community-acquired bacterial pneumonia, or CABP, caused by designated succeptible bacteria.
   The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug  2019/10/09 11:58:26 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on Tuesday. Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 8.) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Albireo Pharma Inc (NASDAQ: ALBO ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BIOLASE Inc (NASDAQ: BIOL ) BioTelemetry Inc (NASDAQ: BEAT ) CELYAD SA/ADR (NASDAQ: CYAD ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Clovis Oncology Inc (NASDAQ: CLVS ) (Goldman reiterated a Sell rating on the stock and cut the price target from $13 to $3.) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Endologix, Inc.

calendar